- Home
- VRAX vs TCRT Comparison
VRAX vs TCRT Comparison
Compare VRAX & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- TCRT
- Stock Information
- Founded
- VRAX 2013
- TCRT 1998
- Country
- VRAX United Kingdom
- TCRT United States
- Employees
- VRAX N/A
- TCRT N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- TCRT Health Care
- Exchange
- VRAX Nasdaq
- TCRT Nasdaq
- Market Cap
- VRAX 4.4M
- TCRT 3.9M
- IPO Year
- VRAX 2022
- TCRT N/A
- Fundamental
- Price
- VRAX $0.55
- TCRT $2.24
- Analyst Decision
- VRAX Strong Buy
- TCRT
- Analyst Count
- VRAX 1
- TCRT 0
- Target Price
- VRAX $3.00
- TCRT N/A
- AVG Volume (30 Days)
- VRAX 1.4M
- TCRT 344.4K
- Earning Date
- VRAX 01-01-0001
- TCRT 08-14-2025
- Dividend Yield
- VRAX N/A
- TCRT N/A
- EPS Growth
- VRAX N/A
- TCRT N/A
- EPS
- VRAX N/A
- TCRT N/A
- Revenue
- VRAX $6,331.00
- TCRT $6,000.00
- Revenue This Year
- VRAX $217,274.83
- TCRT $5,680,500.00
- Revenue Next Year
- VRAX N/A
- TCRT N/A
- P/E Ratio
- VRAX N/A
- TCRT N/A
- Revenue Growth
- VRAX N/A
- TCRT N/A
- 52 Week Low
- VRAX $0.52
- TCRT $1.31
- 52 Week High
- VRAX $4.44
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- VRAX 29.17
- TCRT 43.28
- Support Level
- VRAX $0.52
- TCRT $2.03
- Resistance Level
- VRAX $0.65
- TCRT $2.44
- Average True Range (ATR)
- VRAX 0.05
- TCRT 0.30
- MACD
- VRAX -0.01
- TCRT 0.07
- Stochastic Oscillator
- VRAX 10.32
- TCRT 43.80
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.